This is the first controlled pharmacologic study to demonstrate that treatment of obesity improved PsA disease measures
The approval follows robust data from the SWIFT and ANCHOR Phase III trials
The therapy was well tolerated through Week 24, with a safety profile consistent with Alumis’ Phase 2 data
ADHD is a common, chronic neurodevelopmental disorder that often begins in childhood and can persist into adulthood
The investigational subcutaneous hepcidin mimetic peptide is designed to regulate iron and red blood cell production
REDEMPLO is the first and only Health Canada-approved siRNA therapy for FCS
GlideTech materials are available in several standard base resins and offer customization options for specific applications
Sovaaka offers a deeply personalised diagnostics-led wellness experience that goes beyond routine health checks
Mepolizumab is the first and only monthly biologic in China tested for COPD patients with blood eosinophil counts (BEC) as low as 150 cells/µL
WuXi Biologics has integrated sustainability principles throughout its supplier lifecycle management
Subscribe To Our Newsletter & Stay Updated
